CD8A and neoplasm: For instance, it highlights that neoantigen-specific CD8+T-cell responses were parallel to tumor regression in a responder of NSCLC patients treated with pembrolizumab (130), indicating that anti-PD-1 therapy enhances tumor neoantigen-specific T cell responses.